Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa

被引:11
|
作者
Walker, Rowan [1 ]
Pussell, Bruce A.
机构
[1] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic 3050, Australia
[2] Prince Wales Hosp, Dept Nephrol, Sydney, NSW, Australia
关键词
darbepoetin alfa; epoetin alfa; erythropoietin; haemodialysis;
D O I
10.1111/j.1440-1797.2007.00802.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to compare the within-patient variability in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Data on haemodialysis patients were extracted from the Renal Anaemia Management database from 2003 to 2004. The variance in haemoglobin was calculated for each patient with more than five haemoglobin observations (n = 3619). A mixed model was fitted to the within-patient variances and weighting was based on the number of observations minus 1 for each patient. The model took into account the situation where patients had data on both agents and could therefore act as their own control. The mean within-patient variance in haemoglobin levels for patients receiving darbepoetin alfa was 24% (95% Cl: 18%, 31%) greater than that for patients receiving epoetin alfa (P < 0.0001). The mean haemoglobin level for patients receiving darbepoetin alfa was 11.33 g/dL (95% Cl: 11.27, 11.40) compared with 11.43 g/dL (95% Cl: 11.39, 11.46) for patients receiving epoetin alfa (P < 0.01). There was greater within-patient fluctuation in haemoglobin levels in patients receiving darbepoetin alfa compared with epoetin alfa. The implications of haemoglobin fluctuations on patient outcomes and resource use require further study.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [41] Randomized Equivalence Study Evaluating the Possibility of Switching Hemodialysis Patients Receiving Subcutaneous Human Erythropoietin Directly to Intravenous Darbepoetin Alfa
    Chazot, Charles
    Terrat, Jean Claude
    Dumoulin, Alexandre
    Ang, Kim-Seng
    Gassia, Jean Paul
    Chedid, Khalil
    Maurice, Francois
    Canaud, Bernard
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (02) : 228 - 234
  • [42] Effects of darbepoetin alfa and epoetin beta pegol on iron kinetics in hemodialysis patients
    Sawa J.
    Inaba M.
    Noguchi K.
    Nakagawa C.
    Kuwamura M.
    Kuwamura Y.
    Wada N.
    Kitatani K.
    Kawaguchi Y.
    Kumeda Y.
    Renal Replacement Therapy, 2 (1)
  • [43] Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa
    Hymes, Jeffrey
    Bickimer, Tammy
    Jackson, James H.
    Bookhart, Brahim K.
    Mody, Samir H.
    Piech, Catherine Tak
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (08) : 1931 - 1937
  • [44] Quality of life improvements in dialysis patients receiving darbepoetin alfa
    Fukuhara, Shunichi
    Akizawa, Tadao
    Morita, Satoshi
    Koshikawa, Shozo
    THERAPEUTIC APHERESIS AND DIALYSIS, 2008, 12 (01) : 72 - 77
  • [45] Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
    Prasad, Bhanu
    Jafari, Maryam
    Toppings, Julie
    Gross, Linda
    Kappel, Joanne
    Au, Flora
    CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE, 2020, 7
  • [46] Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis
    Goodkin, DA
    Gimenez, LF
    Graber, SE
    Van Stone, JC
    Egrie, JC
    Okamoto, DM
    CLINICAL NEPHROLOGY, 1999, 51 (06) : 367 - 372
  • [47] A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia
    Justice, G
    Kessler, JF
    Jadeja, J
    Campos, L
    Weick, J
    Chen, CF
    Heatherington, AC
    Amado, RG
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1192 - 1198
  • [48] Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
    Arrieta, Javier
    Moina, Inigo
    Molina, Jose
    Gallardo, Isabel
    Muniz, Maria Luisa
    Robledo, C. Armen
    Garcia, Oscar
    Vidaur, Fernando
    Muoz, Rosa Ines
    Iribar, Izaskun
    Aguirre, Roman
    Maza, Antonio
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 353 - 359
  • [49] Spotlight on Darbepoetin Alfa in the Treatment of Anemia in Patients with Cancer Receiving Chemotherapy
    M. Asif A. Siddiqui
    Gillian M. Keating
    BioDrugs, 2006, 20 : 321 - 323
  • [50] Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels
    Hess, Gregory
    Hill, Jerrold
    Clough, Jeffrey
    Hulnick, Scott
    Nordyke, Robert J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (03) : 815 - 819